Page 111 - 2021年15期

PD-L1 positive，non-small cell lung cancer in China[J]. J renalcell carcinoma[J]. J Immunother Cancer，2018，6（1）：
Med Econ，2019，22（4）：344-349. 124.
[15] ZHANG P F，XIE D，LI Q. Cost-effectiveness analysis of [25] ZHANG B，QI L，WANG X，et al. Phase Ⅱ clinical trial
nivolumab in the second-line treatment for advanced using camrelizumab combined with apatinib and chemo-
esophageal squamous cell carcinoma[J]. Future Oncol， therapy as the first-line treatment of advanced esophageal
2020，16（17）：1189-1198. squamous cell carcinoma[J]. Cancer Commun（Lond），
[16] WAN N，ZHANG T T，HUA S H，et al. Cost-effectiveness 2020，40（12）：711-720.
analysis of pembrolizumab plus chemotherapy with PD- [26] BRIGGS A H，WEINSTEIN M C，FENWICK E A，et al.
L1 test for the first-line treatment of NSCLC[J]. Cancer Model parameter estimation and uncertainty analysis：a re-
Med，2020，9（5）：1683-1693. port of the ISPOR-SMDM modeling good research prac-
[17] LIU Q，LUO X，PENG L，et al. Nivolumab versus doce- tices task force working group-6[J]. Med Decis Making，
taxel for previously treated advanced non-small cell lung 2012，32（5）：722-732.
cancer in China：a cost-effectiveness analysis[J]. Clin Drug [27] 国家医疗保障局，人力资源社会保障部.国家医保局 人
Investig，2020，40（2）：129-137. 力资源社会保障部关于印发《国家基本医疗保险、工伤
[18] WAN X M，PENG L B，MA J A，et al. Economic evalua- 保险和生育保险药品目录（2020 年）》的通知[EB/OL].
tion of nivolumab as a second-line treatment for advanced （2020-12-28）[2021-01-07]. http：//www.nhsa.gov.cn/art/
renal cell carcinoma from US and Chinese perspec- 2020/12/28/art_37_4220.html.
tives[J]. Cancer，2017，123（14）：2634-2641. [28] PITMAN R，FISMAN D，ZARIC G S，et al. Dynamic
[19] ZHOU K，LI Y，LIAO W，et al. Pembrolizumab alone or transmission modeling：a report of the ISPOR-SMDM
with chemotherapy for squamous cell carcinoma of the modeling good research practices task force-5[J]. Value
head and neck：a cost-effectiveness analysis from Chinese Health，2012，15（6）：828-834.
perspective[J]. Oral Oncol，2020，107：104754. [29] 《中国药物经济学评价指南》课题组.中国药物经济学评
[20] WENG X，HUANG X，LI H，et al. First-line treatment 价指南：2020版[M].北京：中国市场出版社，2020：9-15.
with atezolizumab plus nab-paclitaxel for advanced triple- [30] CO-CHAIR L P G，CO-CHAIR A T M M，ANDREW
negative breast cancer：a cost-effectiveness analysis[J]. BRIGGS D，et al. Performance-based risk-sharing arrange-
Am J Clin Oncol，2020，43（5）：340-348. ments：good practices for design，implementation，and
[21] ZHOU K，JIANG C，LI Q. Cost-effectiveness analysis of evaluation：report of the ISPOR good practices for perfor-
pembrolizumab monotherapy and chemotherapy in the mance-based risk-sharing arrangements task force[J].
non-small-cell lung cancer with different PD-L1 tumor Value Health，2013，16（5）：703-719.
proportion scores[J]. Lung Cancer，2019，136：98-101. [31] 中共中央，国务院.中共中央 国务院关于深化医疗保障
[22] LI L Y，WANG H，CHEN X，et al. First-line atezolizu- 制度改革的意见[EB/OL].（2020-03-05）[2020-11-17].
mab plus chemotherapy in treatment of extensive small http：//www.gov.cn/zhengce/2020-03/05/content_5487407.
cell lung cancer：a cost-effectiveness analysis from htm.
China[J]. Chin Med J（Engl），2019，132（23）：2790-2794. [32] 国家医疗保障局.国家医疗保障局关于公布《2020 年国
[23] LIU M，HAN S，ZHENG B，et al. Cost-effectiveness ana- 家医保药品目录调整工作方案》和《2020 年国家医保药
lysis of pembrolizumab in the treatment of advanced re- 品目录调整申报指南》的公告[EB/OL].（2020-08-17）
current metastatic head and neck squamous cell carcino- [2020-11-17].http：//www.nhsa.gov.cn/art/2020/8/17/art_
ma in China and the United States[J]. Cancer Manag Res， 37_3407.html.
2019，11：9483-9493. （收稿日期：2021-01-21 修回日期：2021-05-12）
[24] WU B，ZHANG Q，SUN J. Cost-effectiveness of nivolu- （编辑：刘明伟）
mab plus ipilimumab as first-line therapy in advanced

中国药房 2021年第32卷第15期 China Pharmacy 2021 Vol. 32 No. 15 ·1893 ·